SEPTInvestingStart Free

GH 8-K: Guidance raise

Guardant Health

Filed with the SEC on · accession 0001576280-26-000043

GH filed a 8-K (current report) with the SEC on Nov 5, 2026. Guardant Health reported Q3 2026 revenue of $361.0 million, up 36% year over year, and raised full-year 2026 revenue guidance to $1.36-$1.37 billion (38-40% growth) from the prior $1.34-$1.36 billion. The stock moved -9.0% by the first close after the filing.

Summary of the filing

Guardant Health reported Q3 2026 revenue of $361.0 million, up 36% year over year, and raised full-year 2026 revenue guidance to $1.36-$1.37 billion (38-40% growth) from the prior $1.34-$1.36 billion. The company also reported FDA approvals for Guardant360 CDx companion diagnostics and expanded Shield screening coverage.

For details, click here →How to read a 8-K →

Key details

Q3 2026 total revenue$361.0M
Q3 2025 total revenue$265.2M
Q3 2026 Oncology revenue$231.3M
Q3 2026 Screening revenue$67.6M
Q3 2026 Biopharma & Data revenue$59.0M
Q3 2026 net loss$124.4M
Q3 2026 non-GAAP net loss$38.8M
Full year 2026 revenue guidance low$1.4B
Full year 2026 revenue guidance high$1.4B
Prior full year 2026 revenue guidance low$1.3B
Prior full year 2026 revenue guidance high$1.4B
Cash, cash equivalents, and restricted cash as of September 30, 2026$1.1B
IssuerGuardant Health, Inc.
Companion diagnostic partner for etcamah (camizestrant)AstraZeneca
Shield coverage payerUnitedHealth Group
Shield coverage payerCarelon Healthcare Services
Shield coverage payerEviCore
Co-founder and co-ceoHelmy Eltoukhy
Co-founder and co-ceoAmirAli Talasaz

How GH stock reacted

Close before

$168.58

Nov 4, 2026

First close after

-8.99%

$153.43

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for GH, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for GH?

Click here

Frequently asked questions

What did GH file with the SEC on Nov 5, 2026?

GH filed a 8-K (Guidance raise). Guardant Health reported Q3 2026 revenue of $361.0 million, up 36% year over year, and raised full-year 2026 revenue guidance to $1.36-$1.37 billion (38-40% growth) from the prior $1.34-$1.36 billion. The company also reported FDA approvals for Guardant360 CDx companion diagnostics and expanded Shield screening coverage.

What does a guidance raise mean for GH stock?

Guidance is the company’s own forecast. Investors price stocks on the future, so a raise or cut often moves the stock more than the past quarter’s numbers.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did GH stock react to this filing?

GH closed at $168.58 before the filing and $153.43 on Nov 5, 2026 (-8.99%).

Other GH SEC filings

Get alerts when GH files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
GH overviewGH analysisGH newsLatest SEC filings